The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Dr. John Cush RheumNow
1 year 8 months ago
Small, suspended, post COVID randomized trial, guselkumab failed to show efficacy at reducing proteinuria in 33 SLE pts. Wk24 results, 56% placebo vs. 35% GUS for primary end point., No differences in secondary outcomes or adverse events https://t.co/27imkXkbUn https://t.co/yGdDQlu5v3
A Spanish retrospective registry study of patients with giant cell arteritis (GCA) found that 3-4 years after diagnosis, only 21% of patients with GCA successfully reached the sustained drug-free remission (SDFR). But if SDFR was achieved, the likelihood of experiencing recurrence was low.
Dr. John Cush RheumNow
1 year 8 months ago
In US, peptic ulcer disease affects 1% of population w/ ~ 54 000admitted to hospital annually w/ bleeding peptic ulcers. But only 10% of PUD pts present w/ upper abdominal pain. Prime causes are Helicobacter pylori infection (42%) & NSAID use (36%) https://t.co/0VvA7lI0MQ https://t.co/YWv4SDNVLC
Dr. John Cush RheumNow
1 year 8 months ago
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa
Dr. John Cush RheumNow
1 year 8 months ago
Don’t Buy Guitars (12.6.2024)
This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos;… https://t.co/iaoykvKoCH https://t.co/e0pELS3hMu
Dr. John Cush RheumNow
1 year 8 months ago
ACR24 IL-17 Panel
Join Dr. Philip Mease, Dr. Brian Jaros and Dr. Peter Nash as they discuss key takeaways on IL-17 presentations and data presented at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/04bW7vaMTQ https://t.co/0rTglbW75u
A retrospective cohort study presented at #ACR24 explores the benefits of GLP-1Ras in reducing the risk of end-stage renal disease (ESRD) for patients with lupus nephritis. Drawing on data from the TrinetX global research database, the study examines how GLP-1Ras may reduce ESRD progression in a population where 10-20% progress to ESRD within five years, even with immunosuppressive therapies.
Chronic pain is an acute and debilitating condition that affects millions of people worldwide. And while pain interventions are available, many people struggle without treatment at all.
Dr. John Cush RheumNow
1 year 8 months ago
Navigating Rheumatology Care in Humanitarian Crisis Settings
Dr. Antoni Chan talks with Dr. Martha Dhzhus, who presented Thursday at the Global Summit about rheumatology care in the Ukraine, at the 2024 ACR Convergence meeting in Washington, DC.
https://t.co/k4YTVFnTiF https://t.co/bScrJ28rKi
Dr. John Cush RheumNow
1 year 8 months ago
Metabolic syndrome assoc w/ with response rates in #RA (CDAI MCID OR 0.6), on or off TNFi. Adipokines were associated with metabolic syndrome but were not associated with clinical responses. Data from CERTAIN cohort & CorEvitas registry https://t.co/YH44iTwYTr https://t.co/ec3vb266ym
Dr. John Cush RheumNow
1 year 8 months ago
Lancet forecasts that in Australia 5.4 million will have arthritis 2040, a 31% increase 4.1 mill in 2025. Included 3.2 w/ OA, ~750K w/ RA, & 8500 w/ JIA. OA incr in males from 6.3% to 7% (2040). & 10.8 to 12.2% in F. RA will grow from 1.56 to 1.75% in males and 2.6 to 2.9% in… https://t.co/6DM0ZLlZ05 https://t.co/djPP1cUDOI
While adult rheumatology fellowships have surged in popularity and become quite competitive, more than half of pediatric rheumatology fellowship positions went unfilled in 2024, according to the National Resident Matching Program (NRMP).

